CMS Drug-Eluting Stent Payment Window Open Until Sept. 1
This article was originally published in The Gray Sheet
Executive Summary
A separate ICD-9 code for drug-eluting stents will not be included in the Medicare FY 2003 inpatient payment rule unless FDA approves J&J/Cordis' Cypher before Sept. 1, according to the Centers for Medicare & Medicaid Services
You may also be interested in...
Thoratec Makes Case For Permanent VAD Higher Medicare Reimbursement
Thoratec is expecting CMS to boost Medicare reimbursement for mechanical cardiac assist device implantation based on data showing that the firm's HeartMate XVE left ventricular assist device (LVAD) is a cost-effective destination therapy for end-stage heart failure patients
Thoratec Makes Case For Permanent VAD Higher Medicare Reimbursement
Thoratec is expecting CMS to boost Medicare reimbursement for mechanical cardiac assist device implantation based on data showing that the firm's HeartMate XVE left ventricular assist device (LVAD) is a cost-effective destination therapy for end-stage heart failure patients
Unique Missions Of FDA, CMS Underscored In Presentations To HHS Panel
Ongoing attempts to coordinate FDA and CMS reviews will preserve approval, coverage, coding and payment as distinct processes, agency representatives concurred at the HHS Secretary's Advisory Committee on Regulatory Reform regional hearing June 10